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OThe 1,000th VAD, the great rivalry, and the grand experiment of the
Texas Medical CenterTodd K. Rosengart, MDIn the closing days of 2013, Dr O. H. ‘‘Bud’’ Frazier and the
Texas Heart Institute (THI) team performed their 1,000th
ventricular assist device (VAD) implantation. This landmark
achievement occurred barely more than half a century after
Dr Denton A. Cooley founded THI in 1962 as an institution
dedicated to reducing the ‘‘devastating toll of cardiovascular
disease through innovative programs in treatment, education,
and research.’’1 The 1,000th VAD implantation occurred
almost exactly 50 years after the original 1964 National
Heart Institute (NHI) grant was awarded to Dr Michael E.
DeBakey and the Baylor College of Medicine for the devel-
opment of an artificial heart. The juxtaposition in time of
these 2 auspicious events would begin a unique and remark-
able story—one that would ultimately lead to the realization
of VAD implantation as a standard of care after more than 5
decades of ceaseless effort and unrelenting innovation.
The saga of the 1,000th VAD is a testament to the perse-
verance of Dr Frazier and his colleagues at THI, under the
leadership of Dr Cooley, in designing and perfecting circu-
latory assist devices. However, as noted by Dr Frazier, the
saga is also firmly rooted in foundations first laid at Baylor,
including the pioneering work of DeBakey proteges such as
Dr George P. Noon. After 1969, these key players found
themselves working at rival institutions located a stone’s
throw from each other on the Texas Medical Center
(TMC) campus. The 1,000th VAD implantation therefore
highlights an intriguing story of medical progress and scien-
tific collaboration borne of conflict and competition.BUD FRAZIER’S INITIAL INTEREST
The field of assisted circulation first attracted Frazier in
1965, when, as a 2nd-year medical student at Baylor, he
joined Dr Domingo Liotta in the Baylor laboratories in
research involving the total artificial heart (TAH) project.
Upon Frazier’s graduation in 1967, he received theDeBakey
Award asOutstanding Surgical Student. However, instead of
staying at Baylor after his general surgery residency, Frazier
moved to THI in 1974 for his cardiac training, because VAD
research by that time had moved primarily to the THIFrom the Michael E. DeBakey Department of Surgery, Baylor College of Medicine,
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would lead the development of the pulsatile HeartMate I
pneumatic device (first clinically implanted in 1986); the
first intravascular implantable continuous-flow VAD, the
Hemopump (1988); the HeartMate XVE (first clinically im-
planted in 1991); the Jarvik 2000 heart (2000); the AbioCor
TAH (2001); and the continuous-flow HeartMate II (2003).
Remarkably, except for the AbioCor, Frazier was the first to
implant these devices clinically. He initiated research to
develop the HeartWare VAD in 1994. That same year, he re-
ported the first hospital discharge of a patient with a VAD
and the first long-term clinical use of a VAD (505 days).2
The HeartWare and the HeartMate II are currently the
most widely used VADs in the world.
Dr George Noon worked with the National Aeronautics
and Space Administration to develop the MicroMed DeBa-
key Noon axial-flow pump (1998) and helped to pave the
way for the important role that would be played by
continuous-flow devices as long-term VADs.3 Noon
observed that Frazier’s commitment to ‘‘getting it right’’
has been as important as all the milestones that Frazier
has achieved. For example, when thrombotic complications
with the HeartMate II were encountered early after its clin-
ical deployment, Frazier led the redesign efforts that re-
sulted in a substantially improved device and helped to
make it the most frequently implanted VAD in the world.
As significant as these many accomplishments are in them-
selves, they are even more meaningful within the context of
the 50-year effort of THI and Baylor researchers to develop
the artificial heart and circulatory assist devices.SETTING THE STAGE FOR ASSISTED
CIRCULATION
As DeBakey explained in 2005,4 the determination to
develop VADs and a TAHwas inspired by the highmortality
rate associated with the use of the early heartlung machine
and the observation that some patients undergoing pro-
longed support with aid of that machine would recover their
cardiac function. This led to the conclusion that more pro-
longed support of the failing heart would improve cardiac
recovery. Accordingly, DeBakey remembered, the dawn of
the ‘‘open-heart’’ era in the 1950s created a zeitgeist that
stimulated the pursuit of assisted circulation4 and motivated
DeBakey to establish an experimental laboratory. This lab-
oratory, completewith amachine shop for buildingmechan-
ical prototypes, is still in use (currently for nanotechnology
research), on the 4th floor of the Baylor College of
Medicine. Artificial-heart development efforts at Baylordiovascular Surgery c Volume 147, Number 6 1745
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Laccelerated in the early 1960s after DeBakey recruited a
promising young Argentine researcher, Dr Domingo Liotta,
from the Cleveland Clinic. Liotta had presented his work on
artificial-heart technology in 1961 at the annual meeting of
the American Society for Artificial Internal Organs.2 Soon
thereafter, DeBakey’s testimony to the United States Senate
led to the 1964 NHI funding for an artificial-heart program
at Baylor. DeBakey also forged a research collaboration
with the engineers at neighboring Rice University—another
TMC institution—to lay the final building block in a solid
foundation for pursuing assisted circulation.
During the boom in cardiovascular surgery in Houston led
byCooley andDeBakey, an opportunity soon arose to use the
assist devices that were being engineered in the Baylor labo-
ratories. In July 1963, a patient of Stanley Crawford, named
George Washington, had a cardiac arrest after undergoing
aortic valve replacement andbecame thefirst human recipient
of a VAD. Mr Washington died after 4 days; however, this
experience prompted further innovation. After several more
attempts, the first successful clinical VAD implantation was
performed on August 6, 1966, in Esperanza del Valle Vas-
quez, a patient from Mexico who could not be weaned from
cardiopulmonary bypass (CPB) after a double valve replace-
ment. She was weaned from the VAD after 10 days and
lived for many years. More setbacks were to come, but there
was no turning back after this pioneering accomplishment.
THE ARTIFICIAL HEARTAND THE GREAT
RIVALRY
According to Liotta,5 a case at St Luke’s Episcopal Hos-
pital prompted the first clinical TAH implantation. In 1968,
one of Cooley’s patients developed a ‘‘stone heart’’ after
aortic valve replacement and could not be weaned from
CPB (this problem was not infrequent in that era, when car-
dioplegia was seldom used). In those heady days of the first
heart transplantations, Cooley sought desperately to buy
time for a human transplant by temporarily implanting a
xenograft into his patient. The heart was rejected almost
instantly; however, this event stimulated collaboration be-
tween Cooley and Liotta to perfect a TAH that could be
used clinically.
Because DeBakey was focusing largely on VAD technol-
ogy in the belief that the TAHwould take longer to develop,
Cooley and Liotta feared that their TAH research would be
immutably blocked.6 Nevertheless, Cooley helped to
conduct the animal studies needed to test the TAH proto-
types that Liotta was engineering, thereby sustaining hope
of advancing the TAH. The events that transpired soon
thereafter, in ways that were then unforeseeable, would
have major consequences for the protagonists at Baylor
and would set the stage for the decades-long effort to
develop a reliable VAD.
The fateful day was April 4, 1969. Cooley had agreed to
perform a ventricular aneurysmectomy in a desperate1746 The Journal of Thoracic and Cardiovascular Surattempt to save Haskell Karp, a 47-year-old man dying of
heart failure while awaiting a transplant at St Luke’s Epis-
copal Hospital. In the operating room, Cooley found that
Karp’s heart was extensively scarred; after the aneurysmec-
tomy, he could not be weaned from CPB. Having gained the
approval of Karp and his family beforehand, Cooley pro-
ceeded to implant the TAH that he and Liotta had been
testing.6 In that era before cell phones, E-mails, and text
messages, DeBakey—on a trip to the National Institutes
of Health in Washington—was unreachable. Upon learning
of the events in Houston, DeBakey was outraged, accusing
Cooley of exceeding his medical authority and using his de-
vice without permission. Thus began the feud that would
last for nearly 40 years.
Mr Karp died on April 8, 1969, 4 days after receiving the
TAH and 2 days after the TAH was exchanged for a donor
heart. Amidst the subsequent controversy, Cooley resigned
from Baylor and completed his move to THI. The stage was
set for the famous rivalries between Cooley and DeBakey
and between THI and Baylor. Frazier joined THI a few
years later, and Cooley recruited other innovators such as
John Norman who, with Cooley and George Reul, im-
planted the first VAD as a bridge to transplantation
(1978). The TMC became a bipolar hub for cardiac sur-
gery—led by 2 giants in the field who were always in
eye’s view of each other.
The rivalry between DeBakey and Cooley yielded a par-
adoxical and important result: the talents and resources of
the juxtaposed Baylor–THI powerhouses were mutually
energizing, and a new degree of medical creativity flour-
ished on the TMC campus. This critical mass of competing
talents would eventually contribute to the growth of the
TMC, its other programs, and its other institutions, such
as the MD Anderson Cancer Center and Texas Children’s
Hospital. As a result, the TMC became the largest medical
center in the world.
It is intriguing to speculate in the context of historical
perspective. Might the outcome have been vastly different
if the lines of reporting and communication had been better
in the 1960s? What if DeBakey had left more ‘‘oxygen in
the room’’ for talented and energetic younger faculty mem-
bers such as Cooley? What if Cooley and Liotta had not
acted on their convictions or had not feared for the viability
of their TAH efforts? It is impossible to know whether the
energies of the THI and Baylor surgeons and scientists
would have flagged without the healthy competition
fostered by the proximity of DeBakey and Cooley. Regard-
less, Frazier, Noon, and others express their indebtedness to
the power of that competition.RAPPROCHEMENT
In 2007, rapprochement between DeBakey and Cooley
brought a welcome end to their rivalry.7 Today, the dynamicgery c June 2014
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Lhas come full circle. Dr Cooley has rejoined the faculty of
the Baylor College of Medicine as a Distinguished Profes-
sor Emeritus. Dr Frazier and a younger generation of
surgeon-scientists at THI—led by Drs Hari Mallidi and
William Cohn—are also active members of the Baylor fac-
ulty, rejoining DeBakey’s protege George Noon and others.
Baylor, THI, and St Luke’s have recently formed a unique
and historic corporate partnership.
The formation of this partnership and the milestone of the
1,000th VAD implantation prompt reflections on what has
been learned from this half-century of progress. The crucial
contributions of industrial partners—such as Thermo Cardi-
osystems and its successors, Thoratec Corporation and
HeartWare, Inc.—cannot be ignored. However, the success
story symbolized by the 1,000th VAD implantation is
chiefly one of personal passion, thoughtful perseverance,
and professional competition—with transparency and
collegiality, which are core principles of medical science
and cornerstones of medical progress.
We are indebted to Dr Cooley, Dr Frazier, and their col-
leagues at THI, and to Dr DeBakey, Dr Noon, and their col-
leagues at Baylor, for their historic contributions. It is hoped
and expected that the innovation embodied in their work
will give rise to even more elegantly miniaturized and inter-
nalized long-term VADs. In addition, perhaps the lessons
learned from the great rivalry and the grand experiment
that culminated in the 1,000th VAD implantation will
translate into successful collaborations in the future.
The author thanks Virginia C. Fairchild, Michael A. Rosengart,
William T. Butler, MD, Joseph S. Coselli, MD, and George
P. Noon, MD, for editorial assistance.The Journal of Thoracic and CarReferences
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As I reflect on the circumstances and events that led up to
the 1,000th VAD implantation, I would like to add my con-
gratulations to those of Dr Rosengart and others in honoring
Dr O. H. ‘‘Bud’’ Frazier in this special section of the Texas
Heart Institute Journal. I feel enormous pride and gratitude
for what this milestone represents—both to the Texas Heart
Institute and to heart-failure patients worldwide. I applaud
Dr Frazier for his many accomplishments, which reveal
his remarkable capacity for innovation and leadership
and his lifelong commitment to the alleviation of heart
disease.
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